MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

June 23, 2022 | Ruben Mesa, MD

Share on:
View More
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    View More
    Current Time 0:00
    Duration 0:00
    Loaded: 0%
    Stream Type LIVE
    Remaining Time 0:00
     
    1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Ruben Mesa, MD, reviews the results from the MOMENTUM trial on momelotinib versus danazol in patients with myelofibrosis.